Luxembourg vs Montenegro: Life science patents granted, by technology
Luxembourg
78 patents
in 2023
Montenegro
58 patents
in 2021
Luxembourg rank
18th
Montenegro rank
20th
Life science patents granted, by technology over time
- Luxembourg
- Montenegro
How they compare
Luxembourg currently reports 78 patents against 58 patents in Montenegro, a difference of 20 patents.
That makes Luxembourg's figure about 1.3 times Montenegro's.
Across all 14 years both countries report, Montenegro has been ahead every year.
Luxembourg ranks 18th and Montenegro ranks 20th of 65 countries.
Montenegro has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Luxembourg | Montenegro | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.33 patents | 3.33 patents | 2 patents | Montenegro |
| 2010s | 5.22 patents | 90 patents | 84.78 patents | Montenegro |
| 2020s | 18 patents | 90.5 patents | 72.5 patents | Montenegro |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher life science patents granted, by technology, Luxembourg or Montenegro?
- Luxembourg, at 78 patents against 58 patents in Montenegro as of 2023.
- What is the difference in life science patents granted, by technology between Luxembourg and Montenegro?
- 20 patents, with Luxembourg ahead.
- How many years of comparable data are there for Luxembourg and Montenegro?
- 14 years are reported by both, from 2005 to 2021.
- How do Luxembourg and Montenegro rank globally for life science patents granted, by technology?
- Luxembourg ranks 18th and Montenegro ranks 20th of 65 countries.
- Where does this data come from?
- World Intellectual Property Organization (WIPO) (2025) β processed by Our World in Data, published as Life science patents granted, by technology. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of pharmaceutical patents granted by the filing office in a given year. Pharmaceutical patents typically cover new drugs, biological treatments or vaccines.